

Protective effect of erdosteine against naphthalene-induced oxidative stress in rats

Mr. Asadulla khan¹, Mrs. Pajjoori Sravani², Mrs. Sayeeda Tabassum³

Assistant professor^{1,2,3}

Department of Pharmacognosy,

Global College of Pharmacy, Hyderabad. Chilkur (V), Moinabad (M), Telangana- 501504.

Article Info

Received: 07-07-2022

Revised: 16-08-2022

Accepted: 14-09-2022

ABSTRACT: Here, we look at how erdosteine protects against naphthalene-induced toxicity and what part free radicals play in that process. An oral dosage of 1100 mg naphthalene/kg in maize oil was administered to female Sprague-Dawley rats. Before receiving naphthalene, rats were orally administered 50 mg/kg/day of ergosteine for three days. Twenty-four hours following naphthalene delivery, the rats were beheaded. Activities of glutathione (GSH), malondialdehyde (MDA), sodium (Na⁺), potassium (K⁺) ATPase, and myeloperoxidase (MPO) were measured in liver and kidney tissues. Plasma samples were tested for total antioxidant capacity (AOC), IL-1 α , IL-6, 8-hydroxy-2'-deoxyguanosine (8-OHdG), and aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine levels, and lactate dehydrogenase (LDH) activity. After administering

INTRODUCTION

The majority of crude oils include polycyclic aromatic hydrocarbons (PAHs), which are the primary harmful and long-lasting components. Toxic PAHs have spread over aquatic ecosystems due to the disposal of petroleum products into the ocean (1). The mutagenic/carcinogenic, genotoxic, and cytotoxic effects of certain of these compounds have been established (6). Many commercial products, including mothballs, toilet scent discs, and soil fumigants, contain naphthalene, a general type of polycyclic aromatic hydrocarbons (PAHs). This compound is used in the production of synthetic resins, anthranilic and phthalic acids, and naphthylamines (7, 8).

One possible mechanism by which naphthalene's toxicity manifests is by the formation of hydroxylated compounds, such as 1-naphthol, 2-naphthol, and 1,2-dihydroxynaphthalene, which in turn cause oxidative damage (9, 10). There is evidence that naphthalene exposure increases serum and liver lipid peroxides (11), while decreasing hepatic selenium dependent glutathione peroxidase activity (12). In both humans and rats, exposure to naphthalene causes hemolytic anemia. The same was true for female Sprague-Dawley rats; when given naphthalene (1100 mg/kg), lipid peroxidation in the mitochondria of the liver and brain increased 2.5-fold. 24 hours after treatment, it was shown that naphthalene toxicity is partially caused

naphthalene, the levels of GSH, Na⁺, K⁺-ATPase activity, and plasma AOC were all significantly reduced, while the levels of MDA and MPO were significantly increased in the tissues. In addition, the naphthalene group showed a substantial rise in levels of pro-inflammatory mediators (TNF- α , IL-1 α , IL-6), 8-OHdG, LDH activity, AST, ALT, creatinine, and BUN. Conversely, erdosteine therapy averted all of these naphthalene-induced metabolic alterations. Finally, it seems that erdosteine protects tissues by regulating the production of inflammatory mediators, balancing the oxidant-antioxidant state, and limiting neutrophil invasion.

KEY WORDS: Naphthalene; erdosteine; lipid peroxidation; glutathione; myeloperoxidase

by free radicals and oxidative stress mediated by free radicals (8).

A new mucoactive drug called Erdosteine [N-(carboxymethylthioacetyl)-homo- cysteine thiolactone] has two sulphhydryl groups that are blocked: one is in an aliphatic side-chain and the other is encased in the heterocyclic ring (13). The molecule's free radical scavenging and antioxidant capabilities are activated when the hepatic metabolism frees these chemically inhibited sulfhydryl groups (14). Evidence from many inflammatory models supports its free radical scavenging action, which in turn protects against oxidant-induced tissue damage (15– 18). A similar protective effect of erdosteine against oxidative damage to colonic tissues caused by colitis has been shown by us (19). Based on this backdrop, our goal was to explore the potential protective effects of erdosteine on the hepatic and renal tissues in rats exposed to naphthalene utilizing biochemical analysis.

MATERIALS AND METHODS

Animals

All experimental protocols were approved by the Marmara University School of Medicine Animal Care and Use Committee. Female Sprague-Dawley rats (200– 250 g) were kept at a constant temperature (22 \pm 1^o C) with 12 h light and dark cycles and fed a standard

rat chow.

Experimental Design

Rats were given orogastrically either erdosteine (50mg/kg/ml n=16) or saline (n=16) for 3 consecutive days. On the fourth day, after an overnight fasting with free access to water, half of the saline or erdosteine-treated rats were given 1100mg/kg/ml of naphthalene in corn oil by gavage (naphthalene groups), while the other half of the saline or erdosteine-treated group was given orogastrically corn oil (control groups). All rats were decapitated at 24 hour of naphthalene or corn oil administration. After decapitation of the animals, trunk blood was collected and liver and kidney were carefully dissected and stored at -70°C for the determination of tissue malondialdehyde (MDA) and glutathione (GSH) levels, $\text{Na}^{+}\text{-K}^{+}$ ATPase and myeloperoxidase (MPO) activities.

Biochemical analysis

Blood urea nitrogen (20) and serum AST, ALT (21) and creatinine (22) concentrations and LDH levels (23) were determined spectrophotometrically using an automated analyzer. Plasma levels of tumor necrosis factor alpha (TNF- α), interleukin (IL)-1 α , and IL-6 were quantified according to the manufacturer's instructions and guidelines using enzyme-linked immunosorbent assay (ELISA) kits specific for the previously mentioned rat cytokines (Biosource International, Nivelles, Belgium). The total antioxidant capacity in plasma were measured by using colorimetric test system (ImAnOx, catalogue no. KC5200, Immunodiagnostic AG, D-64625 Bensheim), according to the instructions provided by the manufacturer. The 8-OHdG content in the extracted DNA solution were determined by enzyme-linked immunosorbent assay (ELISA) method (Highly Sensitive 8-OHdG ELISA kit, Japan Institute for the Control of Aging, Shizuoka, Japan). These particular assay kits were selected because of their high degree of sensitivity, specificity, inter- and intra-assay precision, and small amount of plasma sample required conducting the assay.

Malondialdehyde and glutathione assays

Tissue samples were homogenized with ice-cold 150 mM KCl for the determination of malondialdehyde (MDA) and glutathione (GSH) levels. The MDA levels were assayed for products of lipid peroxidation by monitoring thiobarbituric acid reactive substance formation as described previously (24). Lipid peroxidation was expressed in terms of MDA equivalents using an extinction coefficient of $1.56 \times 10^5 \text{ M}^{-1} \text{ cm}^{-1}$ and results are expressed as nmol MDA/g tissue. GSH measurements were performed using a modification of the Ellman procedure (25). Briefly, after centrifugation at 3000 rev./min for 10 min, 0.5 ml of supernatant was added to 2 ml of 0.3 mol/l $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$ solution. A 0.2 ml solution of dithiobisnitrobenzoate (0.4 mg/ml 1% sodium citrate) was added and the absorbance at 412 nm was

measured immediately after mixing. GSH levels were calculated using an extinction coefficient of $1.36 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$. Results are expressed in $\mu\text{mol GSH/g tissue}$.

Myeloperoxidase activity

Myeloperoxidase (MPO) is an enzyme that is found predominantly in the azurophilic granules of polymorphonuclear leukocytes (PMN). Tissue MPO activity is frequently utilized to estimate tissue PMN accumulation in inflamed tissues and correlates significantly with the number of PMN determined histochemically in tissues. MPO activity was measured in tissues in a procedure similar to that documented by Hillegass et al. (26). Tissue samples were homogenized in 50 mM potassium phosphate buffer (PB, pH 6.0), and centrifuged at 41,400 g (10 min); pellets were suspended in 50 mM PB containing 0.5

% hexadecyltrimethylammonium bromide (HETAB). After three freeze and thaw cycles, with sonication between cycles, the samples were centrifuged at 41,400 g for 10 min. Aliquots (0.3 ml) were added to 2.3 ml of reaction mixture containing 50 mM PB, o-dianisidine, and 20 mM H_2O_2 solution. One unit of enzyme activity was defined as the amount of MPO present that caused a change in absorbance measured at 460 nm for 3 min. MPO activity was expressed as U/g tissue.

Measurement of $\text{Na}^{+}\text{-K}^{+}$ -ATPase activity

Measurement of $\text{Na}^{+}\text{-K}^{+}$ -ATPase activity is based on the measurement of inorganic phosphate that is formed from 3 mM disodium adenosine triphosphate added to the medium during the incubation period (27). The medium was incubated in a 37°C water bath for 5 min with a mixture of 100 mM NaCl, 5 mM KCl, 6 mM MgCl_2 , 0.1 mM EDTA, 30 mM Tris HCl (pH 7.4). Following the preincubation period, Na_2ATP , at a final concentration of 3 mM was added to each tube and incubated at 37°C for 30 min. After the incubation, the tubes were placed in an ice bath, and the reaction was stopped. Subsequently, the level of inorganic phosphate was determined in a spectrophotometer (Shimadzu, Japan) at excitation wavelength of 690 nm. The specific activity of the enzyme was expressed as $\mu\text{mol Pi mg}^{-1} \text{ protein h}^{-1}$. The protein concentration of the supernatant was measured by the Lowry method (28).

Statistical analysis

Statistical analysis was carried out using GraphPad Prism 3.0 (GraphPad Software, San Diego; CA; USA). All data were expressed as means \pm SEM. Groups of data were compared with an analysis of variance (ANOVA) followed by Tukey's multiple comparison tests. Values of $p < 0.05$ were regarded as significant.

RESULTS

Treatment with erdosteine resulted in a substantial decrease in both AST and ALT levels ($p < 0.01-0.05$), in

contrast to the considerably higher levels seen in the saline-treated naphthalene group ($p<0.001$). Similarly, the levels of BUN and creatinine, which had a substantial rise in the group treated with saline naphthalene ($p<0.001-0.01$), were restored to the control values by treating with erdosteine ($p<0.01-0.05$). Lactate dehydrogenase in serum The naphthalene group that was treated with saline had a significantly higher nase activity, which is a symptom of widespread tissue damage ($p<0.001$), but this effect was avoided by the administration of erdosteine ($p<0.001$). When compared to the control group, the saline-treated naphthalene group showed a substantial increase ($p<0.001$) in proinflammatory cytokines TNF- α , IL-1 β and IL-6. However, this increase in serum


els, as a marker of oxidative DNA damage, were significantly higher in the saline treated naphthalene group than in control

groups ($p<0.001$) and erdosteine treatment reduced the elevated plasma 8-OHdG levels ($p<0.001$). The total plasma antioxidant capacity is decreased significantly due to naphthalene administration ($p<0.01$), and this decrease was prevented by erdosteine treatment ($p<0.05$, Table 1).


TABLE 1. Effects of erdosteine (50 mg/kg) treatment on some biochemical parameters in the serum of experimental groups. Each group consists of 8 animals. Groups of data were compared with an analysis of variance (ANOVA) followed by Tukey's multiple comparison tests.

Parameters	Control Groups		Naphthalene Groups	
	Saline treated	Erdosteine treated	Saline treated	Erdosteine treated
AST (U/l)	246 \pm 10	250 \pm 12	368 \pm 18***	257 \pm 16**
ALT (U/l)	76.2 \pm 7.7	73.8 \pm 7.8	154 \pm 14.6***	110 \pm 6.3+
Creatinine (U/l)	0.7 \pm 0.1	0.6 \pm 0.1	1.8 \pm 0.2***	0.8 \pm 0.1+++
BUN (U/l)	25.7 \pm 2.1	23.5 \pm 2.1	40.2 \pm 2.5**	28.5 \pm 2.6++
LDH (U/l)	1799 \pm 135	1794 \pm 242	4759 \pm 243***	2416 \pm 101+++
TNF- α (pg/ml)	7.6 \pm 1.1	8.1 \pm 1.3	30.9 \pm 3.1***	13.6 \pm 2.1+++
IL-1 β (pg/ml)	15.5 \pm 1.7	16.5 \pm 1.9	34.2 \pm 3.8***	18.8 \pm 2.2++
IL-6 (pg/ml)	4.9 \pm 0.9	6.5 \pm 1.2	16.1 \pm 1.5***	9.9 \pm 1.2+
8-OHdG (ng/ml)	0.8 \pm 0.1	0.9 \pm 0.1	6.6 \pm 0.9***	2.1 \pm 0.5+++
AOC (pg/ml)	447 \pm 49	424 \pm 53	187 \pm 21**	362 \pm 32+

Data are mean \pm SEM. ** $p<0.01$, *** $p<0.001$ compared to saline treated control group. + $p<0.05$, ++ $p<0.01$, +++ $p<0.001$ compared to saline treated naphthalene group.



cytokine levels caused by naphthalene was abolished ($p<0.001$) after receiving erdosteine therapy. The average amount of malondialdehyde (MDA), a key byproduct of lipid peroxidation, was found to be higher in the liver and kidney tissues following naphthalene administration compared to the control groups ($p<0.001$). On the other hand, erdosteine treatment resulted in a significant reduction of MDA levels ($p<0.01$, Fig. 2) in the naphthalene group.



DISCUSSION

The results show that erdogane was able to significantly reduce naphthelene-induced lipid peroxidation and neutrophil infiltration in the liver and kidney tissues, as antioxidant GSH level and inhibited Na⁺-K⁺-ATPase activity, all thanks to its free radical scavenging capabilities. Excessive oxidative stress is also shown by decreased AOC and elevated levels of LDH, AST, ALT, BUN, creatinine, and 8-OHdG in the blood. Furthermore, the data show that erdosteine administration reversed changes in all tissue parameters, reduced naphthelene-induced oxidative stress indicators in plasma, and enhanced renal and hepatic functioning.

The most vulnerable organs to naphthalene's harmful effects in both people and animals in the lab are the lungs and the lens of the eye (29). Chronic exposure to low doses of naphthelene is the most common cause of human toxicities (30). Administering naphthalene

intraperitoneally at a dose of 200 mg/kg damaged the lungs of mice (30). The formation of cataracts after exposure to naphthalene was documented by Koch et al. (31). Naphthalene caused sister chromatid exchanges in ovary cells from Chinese hamsters, both with and without metabolic stimulation from outside sources. As well as increasing the frequency and severity of chronic inflammation in the lungs and olfactory epithelial

radical spin trapping agent) were also useful in reducing naphthalene-induced cataracts (29) and (41).

It has been shown that erdosteine and its active metabolites significantly inhibit phorbol 12-myristate 13-acetate-induced luminol dependent chemiluminescence

(42). Furthermore, erdosteine's protective effects on inflammation and management in response to hypoxia suggest that it has anti-inflammatory effects by scavenging ROS produced by inflammatory cells. Also, erdosteine protects rats against pulmonary fibrosis and other inflammatory lung disorders (43–45). Research on the protective effects of erdosteine on rat kidneys after renal ischemia/reperfusion (I/R) has been conducted in the lab (46, 47). The rise in kidney oxidant enzyme activity (XO and myeloperoxidase) and MDA levels was reduced in the pretreatment group when given erdosteine at dosages of 10 mg kg⁻¹ day⁻¹, in comparison to the I/R group (46). In addition, the oxidative damage to the liver and kidneys in rats might be avoided by starting oral administration of erdosteine (50 mg kg⁻¹ day⁻¹) two days before to intraperitoneal injection of cisplatin (48). When administered with cisplatin, erdosteine enhanced CAT, GSH-Px, and SOD activity in renal and liver tissues (49).

Lipid peroxidation is a free radical producing mechanism that may be linked to oxidant-induced tissue damage; MDA is a reliable measure of the level of lipid peroxidation (8, 50, 51). Compared to the control group, animals given naphthalene had significantly higher levels of malondialdehyde (MDA) in both the liver and the kidneys. But erdosteine's antioxidant properties kept MDA levels from rising.

It is possible that neutrophil-generated free radicals contribute to this upregulation of lipid peroxidation. Because free radicals not only cause tissue damage directly, but they also seem to induce the accumulation of leukocytes in the affected tissue, which leads to tissue harm indirectly via active neutrophils. The synthesis and

release of reactive oxygen metabolites and cytotoxic proteins into the extracellular fluid by activated neutrophils is known to produce tissue damage. These proteins include proteases, myeloperoxidase, and lactoferrin, among others. Neutrophils secrete MPO and other substances that harm tissues when they are triggered by certain stimuli. This makes it a measure of the amount of neutrophils in the blood. An increase in MPO activity caused by naphthalene may lead to inflammation and organ damage, since neutrophil infiltration is a crucial event in acute inflammation. However, it was shown that proinflammatory cytokines TNF- α , IL-1 β , and IL-6 were considerably elevated, further confirming that naphthalene toxicity is strongly associated with inflammatory processes and oxidative damage. Our data imply that the inhibition of plasma cytokines and tissue neutrophil infiltration is a mediator of the protective effects of erdosteine, as treatment with erdosteine considerably reduced these cytokines and blocked neutrophil infiltration into the injured tissue.

Rats have also been studied to see how erdosteine affects testicular torsion and detorsion (52). Before the rats were twisted or detwisted in the left unilateral testicles, they were given Erdosteine at a dose of 50 mg kg⁻¹ day⁻¹ for two days. By blocking the buildup of free radicals, erdosteine administration mitigated the histological damage caused by testicular torsion and detorsion (49).

To conclude, this study shows that naphthalene oxidative metabolism is a major cause of organ damage. Erdosteine has protective effects because it inhibits neutrophil infiltration, balances oxidant-antioxidant status, and regulates the production of inflammatory mediators. This suggests that Erdosteine may play a role in the treatment of organ failures caused by chemical or drug toxicities in the future.

REFERENCES

1. A. Leonard J.D., Hellou J. Methods for isolating and characterizing polycyclic aromatic chemicals in the gallbladder bile of speckled trout (*Salvelinus fontinalis*). The article was published in 2001 in the journal *Environmental Toxicology and Chemistry* and ran from pages 618 to 623.
2. The authors of the second article are Hendricks JD, Meyers TR, Shelton DW, Casteel JL, and Bailey GS. Exposure of rainbow trout to benzo(a)pyrene by the food and intraperitoneal injection causes hepatocarcinogenesis. The article was published in 1985 in the *Journal of the National Cancer Institute* and ran from March to May.
3. The authors of the article are Malins DC, McCain BB, Brown DW, Varanasi U, Krahn MM, Myers MS, and Chan SL. Bottom-dwelling fish and illnesses of the liver caused by contaminants in its environment. Article published in 1987 in the journal *Hydrobiologia*, volume 49, pages 67–74.
4. Fourth, Pacheco and Santos. Cyclophosphamide and PAH-induced erythrocytic nuclear abnormalities and liver EROD in *Anguilla* *Lynx* sp. *Environmental Toxicology and Safety*, 40(1), 71–76, 1998.
5. Schirmer K, Dixon DG, Greenberg BM, and Bols NC. The capacity of sixteen key PAHs to immediately cause cell death in a rainbow trout gill-derived cell line. The article was published in 1998 in the journal *Toxicology* and ran from page 129 to 141.
6. Míguez JM, Tintos A, Soengas JL, and Gestó M. Brain monoaminergic neurotransmitters in rainbow trout (*Oncorhynchus mykiss*) exposed to naphthalene both acutely and chronically. *Comprehensive Physiology and Pharmacology*, Volume 144, Issue 1, Pages 173–183, 2006.
7. Seventh, Stucker, Bouyer, Mandereau, and Hemon, et al. Examining PAH exposure in retrospect: comparing assessments made by industrial hygiene specialists with those made using a work exposure matrix. *Global Journal of Epidemiology*, 22: 5106–5112, 1993.
8. In the study conducted by Vuchetich PJ, Bagchi

D, Bagchi M, Hassoun EA, Tang L, and Stohs SJ. The oxidative stress in rats caused by naphthalene and how vitamin E succinate protects them. Publication date: 1996, volume 21, pages 577-590, in the journal Free Radical Biology and Medicine.

9. 8. Cho M, Buckpitt A., Hammock B., Jedrychowski R. Naphthalene metabolites bind reactively to albumin and hemoglobin. In 1994, the article was published in Fundam Appl Toxicology and ran from page 26 to 33.
10. 10. Miller, Miller, Powell, and Cohen, G. Microsomal metabolism of 1-naphtol leads to the formation and identification of glutathione-Naphthoquinone conjugates. Edited by Kocsis, Jollow, Witmer, Nelson, and Snyder. Volume III: Biochemical Reactive Intermediates. New York: Plenum Press, 1986, pp. 391-398.
11. eleven. Yamachichi T, Komura S, and Yagi K. Albino rats given naphthalene had elevated serum lipid peroxide levels. Biochemical Journal, 13(1), 1986.
12. 12. Germansky, M, Jamall S. Role of naphthalene in rat tissue peroxidation, glutathione peroxidases, and superoxide dismutase: an organ-specific study. Publication date: 1998, volume 61, pages 480–483.
13. 13. Evaluation of the antioxidant effects of erdosteine's SH metabolite I on oxidative bursts in human neutrophils. BragaPC, Dal Sasso M, and Zuccotti T. Medicine research, 50: 739–746 in 2000.
14. The authors of the article are Inglesi, Nicola, Fregnan, Bradamante, and Pagani. How erdosteine's enantiomers are synthesized and their free radical scavenging capabilities. Volume 40, Issues 703–708, 1994, edited by Farmaco.
15. A group of researchers including Boyaci, Maral, Turan, Basyigit, Dillioglugil, Yildiz, Tugay, Pala, and Ercin conducted the study. Modulation of bleomycin-induced lung fibrosis in rats by erdosteine. The publication year of this article is 2006.